Humanized ANTI-SCG3 antibody

Humanized ANTI-SCG3 antibody has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jun 15, 2025: “Age-independent anti-angiogenic therapy for choroidal neovascularization by targeting secretogranin III”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on humanized ANTI-SCG3 antibody

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: National Eye Institute and 2 more
  • 1 of 1 finding with company ties
  • Animals1

What did studies of humanized ANTI-SCG3 antibody find?

1

Studies of humanized ANTI-SCG3 antibody measured one outcome, choroidal neovascularization.

Choroidal neovascularization

downin mice1

1 study
  1. Humanized ANTI-SCG3 antibody decreases choroidal neovascularization in mice (laser-induced CNV).

    Animalslaser-induced CNVhumanized

More on Choroidal neovascularization

Latest